D-Index & Metrics Best Publications
Bonaventura Clotet

Bonaventura Clotet

Immunology
Spain
2022

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 75 Citations 21,910 329 World Ranking 817 National Ranking 7
Medicine D-index 104 Citations 44,140 709 World Ranking 3119 National Ranking 41

Research.com Recognitions

Awards & Achievements

2022 - Research.com Immunology in Spain Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Virus
  • Acquired immunodeficiency syndrome

Bonaventura Clotet mostly deals with Virology, Immunology, Viral load, Internal medicine and Virus. Bonaventura Clotet has researched Virology in several fields, including Peripheral blood mononuclear cell and Drug resistance. As a part of the same scientific study, Bonaventura Clotet usually deals with the Immunology, concentrating on Acquired immunodeficiency syndrome and frequently concerns with Transmission, Family medicine and Hepatitis C virus.

His study in Viral load is interdisciplinary in nature, drawing from both Clinical trial, Regimen, Tolerability, Human leukocyte antigen and Enfuvirtide. His work deals with themes such as Gastroenterology, Placebo, Surgery and Ritonavir, which intersect with Internal medicine. In his study, Integrase inhibitor is strongly linked to Pharmacology, which falls under the umbrella field of Ritonavir.

His most cited work include:

  • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. (463 citations)
  • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials (419 citations)
  • Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study (316 citations)

What are the main themes of his work throughout his whole career to date?

Bonaventura Clotet mainly focuses on Virology, Internal medicine, Immunology, Viral load and Virus. His Virology research integrates issues from Reverse transcriptase, Drug resistance and Genotype. Bonaventura Clotet interconnects Gastroenterology, Oncology and Ritonavir in the investigation of issues within Internal medicine.

His research in Ritonavir intersects with topics in Protease inhibitor, Darunavir, Lopinavir and Pharmacology. His work on Acquired immunodeficiency syndrome expands to the thematically related Immunology. His Viral load research incorporates themes from Surgery, Adverse effect, Placebo, Pharmacotherapy and Lamivudine.

He most often published in these fields:

  • Virology (35.00%)
  • Internal medicine (34.79%)
  • Immunology (29.79%)

What were the highlights of his more recent work (between 2016-2021)?

  • Internal medicine (34.79%)
  • Immunology (29.79%)
  • Immune system (7.08%)

In recent papers he was focusing on the following fields of study:

His main research concerns Internal medicine, Immunology, Immune system, Virology and Viral load. Internal medicine is closely attributed to Oncology in his work. The study incorporates disciplines such as Phenotype and Prospective cohort study in addition to Immunology.

Bonaventura Clotet has included themes like Epitope, Cytotoxic T cell and Monoclonal antibody in his Immune system study. His research integrates issues of Inoculation, Antibody and Severe acute respiratory syndrome coronavirus 2 in his study of Virology. His studies in Viral load integrate themes in fields like Pharmacotherapy and Viral replication.

Between 2016 and 2021, his most popular works were:

  • Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. (114 citations)
  • Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. (38 citations)
  • A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. (38 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Acquired immunodeficiency syndrome
  • Virus

The scientist’s investigation covers issues in Internal medicine, Immunology, Immune system, Viral load and Oncology. Many of his studies involve connections with topics such as Prospective cohort study and Immunology. His Immune system study combines topics from a wide range of disciplines, such as Vaccination, Virology and Antibody, Neutralization, Monoclonal antibody.

He combines subjects such as Antibody-dependent cell-mediated cytotoxicity and Antigen with his study of Virology. His Viral load study incorporates themes from Discontinuation, Dolutegravir, Maintenance therapy, Integrase inhibitor and Pharmacotherapy. His Randomized controlled trial research is multidisciplinary, incorporating elements of Lamivudine and Incidence.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson.
The Lancet (2007)

710 Citations

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper.
The Lancet (2007)

650 Citations

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Bonaventura Clotet;Judith Feinberg;Jan Van Lunzen;Marie Aude Khuong-Josses.
The Lancet (2014)

484 Citations

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley.
The Lancet (2006)

439 Citations

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection

Martin S. Hirsch;Scott M. Hammer;Victoria A. Johnson;Daniel R. Kuritzkes.
(2000)

340 Citations

Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication.

Miguel A Martínez;Arantxa Gutiérrez;Mercedes Armand-Ugón;Julià Blanco.
AIDS (2002)

322 Citations

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Joseph J. Eron;Bonaventura Clotet;Jacques Durant;Christine Katlama.
The Journal of Infectious Diseases (2013)

299 Citations

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.

Remko Van Leeuwen;Christine Katlama;Robert Murphy;Kathleen Squires.
AIDS (2003)

269 Citations

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

Roy T. Steigbigel;David A. Cooper;Hedy Teppler;Joseph J. Eron.
Clinical Infectious Diseases (2010)

256 Citations

Update of the drug resistance mutations in HIV-1: Fall 2006.

Victoria A Johnson;Francoise Brun-Vezinet;Bonaventura Clotet;Daniel R Kuritzkes.
Topics in HIV medicine : a publication of the International AIDS Society, USA (2006)

249 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Bonaventura Clotet

Javier Martinez-Picado

Javier Martinez-Picado

University of Vic

Publications: 146

Mark A. Wainberg

Mark A. Wainberg

McGill University

Publications: 124

Vincent Soriano

Vincent Soriano

Hospital Universitario La Paz

Publications: 122

Adriano Lazzarin

Adriano Lazzarin

Vita-Salute San Raffaele University

Publications: 84

Huldrych F. Günthard

Huldrych F. Günthard

University of Zurich

Publications: 79

Julià Blanco

Julià Blanco

IrsiCaixa

Publications: 77

Christine Katlama

Christine Katlama

Université Paris Cité

Publications: 76

José A. Esté

José A. Esté

Autonomous University of Barcelona

Publications: 76

Bruce D. Walker

Bruce D. Walker

Harvard University

Publications: 74

Carlo Federico Perno

Carlo Federico Perno

University of Milan

Publications: 73

José M. Gatell

José M. Gatell

University of Barcelona

Publications: 72

Jens D. Lundgren

Jens D. Lundgren

Rigshospitalet

Publications: 71

Dominique Costagliola

Dominique Costagliola

Université Paris Cité

Publications: 69

Andrea Antinori

Andrea Antinori

Catholic University of the Sacred Heart

Publications: 67

Felipe García

Felipe García

University of Barcelona

Publications: 67

Andrew N. Phillips

Andrew N. Phillips

University College London

Publications: 64

Trending Scientists

Stefan Decker

Stefan Decker

RWTH Aachen University

Carme Torras

Carme Torras

Spanish National Research Council

Mark M. Wilde

Mark M. Wilde

Louisiana State University

Simon A. Parsons

Simon A. Parsons

Cranfield University

Yue Lin

Yue Lin

University of Science and Technology of China

Richard M. Kamens

Richard M. Kamens

University of North Carolina at Chapel Hill

Nathalie Tufenkji

Nathalie Tufenkji

McGill University

Didier Hannequin

Didier Hannequin

Inserm : Institut national de la santé et de la recherche médicale

Nora J. Besansky

Nora J. Besansky

University of Notre Dame

Karl Walter Bock

Karl Walter Bock

University of Tübingen

Alessandro Rossi

Alessandro Rossi

University of L'Aquila

Hope S. Rugo

Hope S. Rugo

University of California, San Francisco

Richard Poulsom

Richard Poulsom

Queen Mary University of London

Heribert Schunkert

Heribert Schunkert

Technical University of Munich

Maurilio Marcacci

Maurilio Marcacci

University of Bologna

Charlie Foster

Charlie Foster

University of Bristol

Something went wrong. Please try again later.